CINECA IRIS Institutional Research Information System

BRUNETTO, MAURIZIA ROSSANA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.441
AS - Asia 13.027
EU - Europa 7.247
SA - Sud America 2.568
AF - Africa 329
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 10
Totale 49.641
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.664
CN - Cina 3.913
SG - Singapore 3.641
HK - Hong Kong 2.934
BR - Brasile 2.171
IT - Italia 1.820
SE - Svezia 1.190
BG - Bulgaria 1.035
VN - Vietnam 944
DE - Germania 662
CA - Canada 636
RU - Federazione Russa 519
KR - Corea 516
UA - Ucraina 450
GB - Regno Unito 398
TR - Turchia 336
FI - Finlandia 300
FR - Francia 237
CH - Svizzera 189
IN - India 172
AT - Austria 168
AR - Argentina 164
BD - Bangladesh 99
MX - Messico 75
CI - Costa d'Avorio 70
EC - Ecuador 70
JP - Giappone 69
ID - Indonesia 68
ZA - Sudafrica 68
NL - Olanda 61
IQ - Iraq 47
PK - Pakistan 43
CO - Colombia 41
BE - Belgio 34
EG - Egitto 33
SA - Arabia Saudita 31
MA - Marocco 29
UZ - Uzbekistan 29
PY - Paraguay 27
PL - Polonia 26
SN - Senegal 25
VE - Venezuela 25
CL - Cile 24
BJ - Benin 22
ES - Italia 21
RO - Romania 20
CZ - Repubblica Ceca 19
PE - Perù 19
AE - Emirati Arabi Uniti 18
IE - Irlanda 17
KE - Kenya 17
NG - Nigeria 16
PH - Filippine 16
UY - Uruguay 16
IR - Iran 15
NP - Nepal 15
TW - Taiwan 15
AU - Australia 13
GR - Grecia 13
MY - Malesia 13
JO - Giordania 12
TN - Tunisia 12
TT - Trinidad e Tobago 12
ET - Etiopia 11
JM - Giamaica 11
AL - Albania 10
DZ - Algeria 10
TH - Thailandia 10
BO - Bolivia 9
LT - Lituania 9
AZ - Azerbaigian 8
HU - Ungheria 8
KZ - Kazakistan 8
OM - Oman 7
DO - Repubblica Dominicana 6
RS - Serbia 6
SY - Repubblica araba siriana 6
CR - Costa Rica 5
DK - Danimarca 5
EU - Europa 5
GE - Georgia 5
HN - Honduras 5
IL - Israele 5
NZ - Nuova Zelanda 5
PT - Portogallo 5
XK - ???statistics.table.value.countryCode.XK??? 5
BA - Bosnia-Erzegovina 4
KG - Kirghizistan 4
MR - Mauritania 4
NI - Nicaragua 4
BB - Barbados 3
EE - Estonia 3
LB - Libano 3
LK - Sri Lanka 3
LV - Lettonia 3
MD - Moldavia 3
MN - Mongolia 3
PA - Panama 3
PS - Palestinian Territory 3
SV - El Salvador 3
Totale 49.584
Salva come PNG Salva come JPEG
Città #
Fairfield 3.088
Woodbridge 3.055
Hong Kong 2.921
Ashburn 2.792
Singapore 2.013
Ann Arbor 1.809
Houston 1.753
Dallas 1.443
Seattle 1.243
Sofia 1.035
Cambridge 1.011
Wilmington 972
Chandler 946
Shanghai 885
Santa Clara 873
Beijing 756
New York 729
Hefei 709
Milan 676
Jacksonville 573
Ottawa 562
Seoul 507
Boardman 500
Princeton 440
Lawrence 430
Medford 355
Des Moines 328
Nanjing 273
Los Angeles 270
Ho Chi Minh City 217
Istanbul 185
Bern 178
San Diego 168
Buffalo 167
Dearborn 160
Redondo Beach 159
Frankfurt am Main 155
Dong Ket 152
São Paulo 145
Vienna 128
Nanchang 125
Izmir 105
Munich 103
Jüchen 100
Serra 91
Hanoi 82
Kunming 79
Ogden 78
London 77
Rio de Janeiro 73
Florence 71
Abidjan 69
Chicago 68
Shenyang 68
Changsha 67
Turku 67
Nuremberg 66
Pisa 64
Council Bluffs 61
Rome 59
Belo Horizonte 57
Hebei 51
Redwood City 48
Brasília 46
Tokyo 45
Jiaxing 42
Washington 42
Tianjin 41
Boulder 40
Norwalk 40
San Jose 37
Curitiba 35
Paris 34
Salvador 34
Pune 33
Campinas 30
Jinan 29
Porto Alegre 29
Brussels 28
Guangzhou 28
Tashkent 28
Johannesburg 27
Lucca 27
San Francisco 27
Da Nang 25
Dakar 25
Fuzhou 25
Lancaster 25
Dhaka 24
The Dalles 24
Brooklyn 22
Columbus 22
Cotonou 22
Quito 22
Montreal 21
Toronto 21
Bremen 20
Falls Church 20
Guarulhos 20
Guayaquil 20
Totale 37.570
Salva come PNG Salva come JPEG
Nome #
Active HBV replication in HBsAg carriers with chronic Delta infection 237
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study 229
Development of a liver model using PAM scaffolds in static and dynamic conditions 216
2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. 214
Serum markers of hepatitis B virus replication, liver histology and intrahepatic expression of hepatitis B core antigen 212
Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen 207
Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound 207
Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment 195
Sequence variation in hepatitis C viral isolates 193
Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D 192
A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B 191
A precore-defective mutant of hepatitis B virus associated with e antigen-negative chronic liver disease 187
REPLICATING AND VIRION SECRETING HEPATITIS B MUTANT VIRUS UNABLE TO PRODUCE PRES2 PROTEIN 182
Hepatitis delta virus, a model of liver cell pathology 180
Hepatitis G virus RNA in the serum of patients with elevated gamma glutamyl transpeptidase and alkaline phosphatase: a specific liver disease? 180
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with graves’ ophthalmopathy 180
Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations 179
T-lymphocyte response to hepatitis C virus in different clinical courses of infection 179
A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers 179
The natural history of chronic delta hepatitis 177
Expression of estrogen receptor mRNA in tumorous and non-tumorous liver tissue as detected by in situ hybridization 176
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases 176
Precore mutant hepatitis B virus and outcome of chronic infection and hepatitis in hepatitis B e antigen-positive children 173
High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders 173
2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. 171
Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values 170
A multiphase model of th dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alfa2a, lamivudine and combination therapy 170
Variants of hepatitis B virus 169
Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects 169
Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview 169
Severe liver injury possibly due to verapamil 168
Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B 168
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study 168
Liver stiffness, a non-invasive marker of liver disease in the HBV carrier 167
Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers 167
Hepatitis C virus infection in type II essential mixed cryoglobulinemias 165
Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging 165
Hepatitis B virus unable to secrete e antigen 164
Software and expert system for the management of chronic hepatitis B 164
Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study 164
Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin 163
Asymptomatic hypermylasemia and hyperlipasemia associated with aripiprazole 163
Multicenter evaluation of the elecsys hepatitis B surface antigen quantitative assay 163
Characterization of hepatitis delta antigen gene of a highly pathogenic strain of hepatitis delta virus 162
Possible immunopathogenesis for fibrosing cholestatic hepatitis 162
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 162
Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C 160
Quantitative analysis of wild-type and HBeAg minus hepatitis B viruses by a sequence-dependent primer extension assay 158
Problems in diagnosing viral hepatitis 158
Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research 158
Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey 157
A dynamic analysis of IgM anti-HCV helps to distinguish hepatitis C from acute rejection in liver transplant patients 157
Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences 157
Introduction to 'Hepatitis B virus heterogeneity--a means to personalized care' 157
New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases 157
'e' antigen defective hepatitis B virus and course of chronic infection 157
IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease? 156
Validation and comparison of different PCR-based methods for detection of Hepatitis B virus precore region mutants 156
Hepatitis B virus surface antigen levels: a guide to sustained response to Peginterferon alfa-2a in HBeAg-negative chronic hepatitis B 156
Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C 155
White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths 155
Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells 155
Uridine diphosphate glucoronosyl transferases, candidate antigens of liver-kidney microsomal antibodies in hepatitis delta virus-infected patients 154
Comparable function of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors 154
Potential applications of extracorporeal photopheresis in liver transplantation 154
Patterns of natural killer cell function activation in response to interferon in chronic HBsAG positive hepatitis: relationship with the state of viral infection and with the early clinical response 153
Role of hepatitis delta virus infection in hepatocellular carcinoma 153
Personalized Therapy in chronic viral hepatitis 152
Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares 152
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 152
Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection. 152
Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares 151
Rapidly progressive HBsAg hepatitis in Italy: a syndrome of Delta hepatitis virus superinfection 150
Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection 149
Laparoscopic robot-assisted distal splenorenal shunt 148
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 148
Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease 148
Diagnosis and monitoring of hepatitis virus infection in liver transplant patients 148
Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis 147
Quantitative detection of hepatitis C virus RNA in the serum of patients with chronic hepatitis C treated with interferon: a pilot study 147
Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. 147
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 147
Asymptomatic hyperamylasemia and hyperlipasemia associated with aripiprazole 146
Does HBeAg minus HBV modify the course of HDV superinfection? 145
Different aspects of HDV and HBV reinfections and liver disease in orthotopic liver transplant (OLT) 145
Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. 145
Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders 144
Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders 144
Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis 143
A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2a (40kd) (PEGASYS (R)), lamivudine, or PEGASYS (R) plus lamivudine combin 143
Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells 142
AISF position paper on HCV in immunocompromised patients. 141
Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc 140
Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer 140
Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic Hepatitis B 140
Ruolo degli acidi nucleici e marcatori immunologici nella diagnosi e gestione del portatore cronico di virus epatici maggiori (B, C e D) 139
Horse antilymphocytic globulin in hepatitis B exacerbation after bone marrow transplantation adoptive immunity transfer 139
Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy 139
Is hepatitis C virus RNA detectable in dialysis ultrafiltrate? 138
Diagnostic markers of chronic hepatitis B infection and disease” 138
Totale 16.333
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.577
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.577
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.932 0 0 0 0 0 123 203 237 356 235 220 558
2021/20224.379 130 272 73 270 777 677 171 201 245 212 161 1.190
2022/20233.247 615 321 205 252 340 459 41 232 533 24 181 44
2023/20243.413 436 318 378 174 496 817 63 75 79 40 84 453
2024/202511.332 37 506 120 524 545 900 1.063 704 1.232 1.727 1.540 2.434
2025/20268.727 747 2.142 2.073 1.737 1.021 1.007 0 0 0 0 0 0
Totale 50.302